Search Results for: vedolizumab

August 24, 2017August 25, 2017

Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment

News

Takeda Pharmaceutical Company has submitted a new drug application to Japanese regulators for vedolizumab (MLN0002) as a treatment for adults with moderate to severe ulcerative colitis. Ulcerative colitis “is a chronic, ... Read more

Entyvio (Vedolizumab)

Entyvio (vedolizumab) is a maintenance treatment for moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD), types of inflammatory bowel disease (IBD). Both the U.S. Food and Drug Administration ... Read more

January 25, 2021January 25, 2021

Canada Approves At-home Entyvio Injection for Crohn’s

Crohn's Disease, News

Health Canada has approved a self-injectable subcutaneous (under-the-skin) form of Entyvio (vedolizumab) as an at-home maintenance therapy for adults with Crohn’s disease (CD). The approval follows an earlier decision to ... Read more

January 11, 2021January 11, 2021

Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study

IBD News, News, Ulcerative colitis

Abivax has published a review study summarizing the mechanisms, as well as the previously undisclosed clinical benefits of ABX464, its treatment candidate for people with inflammatory diseases, including ulcerative colitis ... Read more

September 21, 2020September 21, 2020

ABX464 Effective at Keeping UC Patients in Remission Over Time, Data Show

News, Ulcerative colitis

ABX464, Abivax’s treatment candidate for ulcerative colitis (UC), continues to be safe and effective over time at keeping patients with moderate-to-severe UC in clinical remission, according to two-year data from a ... Read more

May 11, 2020May 11, 2020

Entyvio At-home Injection Approved in Europe to Treat Adults With IBD

Crohn's Disease, News, Ulcerative colitis

The European Commission has approved a subcutaneous (under-the-skin) formulation of Entyvio (vedolizumab) for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). This ... Read more

April 20, 2020April 20, 2020

New Guidelines Issued on Treating IBD Patients During COVID-19 Pandemic

News

Leading experts have drafted new guidelines to aid gastroenterologists in the management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic, according to an American Gastroenterological Association (AGA) press ... Read more

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more

March 11, 2020March 11, 2020

In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio

News

Royalty Pharma has bought Massachusetts General Hospital’s (MGH) royalty interest in the inflammatory bowel disease (IBD) therapy Entyvio (vedolizumab) for $94 million. Produced by Millennium Pharmaceuticals, which is part of Takeda, ... Read more

March 4, 2020March 4, 2020

Panel Recommends European Approval of Entyvio At-Home Injection

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of a subcutaneous (under-the-skin) injection of Entyvio (Vedolizumab), the gut-selective maintenance therapy for ... Read more